MMI and CXR show Ru better than Pt?

Published: 9-Feb-2005

Medical Marketing International (MMI), a Cambridge, UK-based pharmaceutical development company has shown that lead ruthenium compounds within its portfolio of cancer therapies show toxicity at an even safer level than the safest cancer drug currently available, when tested in an industry standard laboratory model.


Medical Marketing International (MMI), a Cambridge, UK-based pharmaceutical development company has shown that lead ruthenium compounds within its portfolio of cancer therapies show toxicity at an even safer level than the safest cancer drug currently available, when tested in an industry standard laboratory model.

MMI has already shown that the ruthenium cancer therapies within its wholly-owned subsidiary, Oncosense, appear in laboratory tests to be more powerful than the platinum-based drugs which have been some of the most successful cancer drugs for decades and which had peak sales of $5bn. Efficacy of these compounds has also been independently demonstrated in both human cancer cells and in vivo models. MMI recently announced that patents in USA and Europe, the two biggest markets have been granted, and other patents are pending. MMI used the Dundee-based specialist, CXR Biosciences to test the most promising ruthenium compounds for potential toxicity.

Mark Burton, technical manager at MMI said: 'We chose CXR because of their highly regarded expertise in screening new drugs for harmful effects. Not only did CXR deliver the results on time and on budget, they were able to show that our ruthenium cancer therapies demonstrate a low toxicity profile. These results, when added to the existing efficacy data show that ruthenium has great clinical potential.'

Executive chairman of MMI Group, David Best, commenting on these results said: 'Ruthenium is only one of MMI's portfolio of excellent drug candidates, but already data show it to be potentially the most effective drug against serious cancers like lung, colon and ovarian. This new data from CXR shows ruthenium to be potentially relatively safe too. If these results are confirmed in the clinical trials, then ruthenium may improve significantly on the standard treatment for cancer patients and become a major commercial success in a cancer therapy market that was worth $42bn in 2004 and continues to grow in double-digit figures.'

See more

You may also like

Medical Devices

Syensqo introduces medical-grade Amodel PPA for single-use, high-temperature medical devices

Read more
A new medical-grade Amodel PPA delivers high heat resistance, electrically insulative properties, and biocompatibility for advanced single-use medical instruments and assemblies

Trending Articles

  1. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  2. Abselion launches AAVX and AAV9 Total Capsid Quantification Kits Ready-to-use solution for Amperia benchtop platform supports rapid, reliable quantification across a range of serotypes
  3. diaago and Peak Analysis & Automation partner to bring practical automation solutions to research laboratories Using diaago's customer-first approach with PAA’s decades of expertise in laboratory robotics, the collaboration promises to deliver solutions to streamline workflows, boost throughput and reduce bottlenecks
  4. Suncombe and Kindeva collaborate to deliver low-carbon inhalers to the NHS The partnership will develop next-generation pressurised metered-dose inhalers with low Global Warming Potential propellants, helping the NHS move closer to its Net Zero target
  5. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Medical Devices

Syensqo introduces medical-grade Amodel PPA for single-use, high-temperature medical devices

A new medical-grade Amodel PPA delivers high heat resistance, electrically insulative properties, and biocompatibility for advanced single-use medical instruments and assemblies
Manufacturing

Sapio Sciences introduces world’s first 3rd-generation ELN

Sapio ELaiN is an AI-powered lab notebook designed to act as a scientific collaborator
Manufacturing

Signal Group launches MCERTS approved VOC emissions monitor

New SOLAR CEMNEX analyser offers advanced compliance and connectivity features
Research & Development

Genoskin raises $8.7m in its first funding round to advance its ethical, human-based alternatives to animal testing

The financing will drive Genoskin’s next phase of growth, with a view to scaling up operations in both the US and France
You need to be a subscriber to read this article.
Click here to find out more.
Packaging

Cloud labelling and serialisation: the new frontline of traceability in drug delivery

As drug delivery evolves to accommodate a new wave of data-driven innovation, the need for traceability and compliance throughout the supply chain is paramount. Innovative cloud-based solutions enable pharmaceutical companies to navigate these demands with confidence
Manufacturing

Sharp boosts autoinjector and pen assembly line capability with $20m investment in Pennsylvania facility

The money will boost its autoinjector and pen assembly, labelling and packaging lines across various therapeutic areas at its facility in Macungie, meeting the rising demand for injectables
Manufacturing

L.B. Bohle to showcase machines for OSD, food and nutraceuticals at PACK EXPO 2025

Company to present advanced blending, particle sizing and coating technologies at Las Vegas event
Subscribe now